Abingdon Health and DCN Dx have announced a commercial partnership to provide Abingdon Health’s proprietary AppDx smartphone m-Health technology to DCN Dx’s customer base.
Under the terms of the agreement, the companies will work together to provide DCN Dx’s customers with lateral flow testing solutions that incorporate Abingdon Health’s smartphone AppDx technology.
AppDx is cutting-edge m-Health software that turns a smartphone into a lateral flow reader. By utilizing cameras and connectivity within smartphones, AppDx enables rapid test results to be captured and presented locally to the user or through a cloud connected data portal. AppDx’s provision of lab-quality results in any location creates flexible testing solutions and allows real-time health monitoring and management.
Chris Yates, CEO, of Abingdon Health:
“We are delighted to partner with DCN Dx. We believe our AppDX technology has an important role to play in the decentralization of rapid testing, and DCN Dx is a great partner to support the roll-out of our recently launched technology.
Brendan O’Farrell, President and Founding Partner of DCN Dx:
“This partnership will make important rapid test data more readily accessible to a wider range of customers. Now, more than ever, digital collection of data from point of care tests is critical and AppDx provides an ideal solution,” said Dr. Brendan O’ Farrell, DCN Dx’s president. “In these challenging times, DCN Dx is excited to utilize the cutting edge technology offered by Abingdon Health.”
About Abingdon Health
Abingdon is a UK-based developer and manufacturer of lateral flow tests and smartphone reader solutions. Abingdon offers development and manufacturing services for customers looking to develop new assays or looking to transfer existing laboratory-based assays to a lateral flow format. Abingdon takes projects from initial concept through to routine and large-scale manufacturing.
Abingdon is headquartered in York, England. www.abingdonhealth.com
About DCN Dx
DCN Dx is a contract developer and manufacturer of lateral flow devices for immunoassay or detection of molecular product at the point of need. Since its founding more than 14 years ago, DCN Dx has been committed to furthering the rapid diagnostic test market through the continued evolution of technologies and applications related to lateral flow assays. For more information about DCN Dx, visit dcndx.com.
